SciRent SciRent
  • Home
  • Who we are
  • What we do
  • Team
  • News and events
  • Contact

SPIHF-203 Latest News

Barcelona, 27 August 2017

Iphone

Also in news

SPIHF-203 Latest News

EtiCS Trial Latest News

KYMA Trial Latest News

KYMA Trial

First patient enrolled in ETiCS trial

MOLITOR introduced at the Heart Failure Congress 2013

27 august 2017
Results of the SPIHF-203 study were presented to Investigators during the ESC - European Society of Cardiology held in Barcelona. The results were presented by James Carr, Chief Clinical Development Officer at Stealth BioTherapeutics Inc. The more details about this trail we can expect very soon.

3 May 2017
Last patient completed Follow up visit on 3rd of May 2017.

31 March 2017
Recruitment for the SPIHF-203 is completed. The last patient was enrolled at Clinical Hospital Center Zvezdara on 31 mart 2017.

15 September 2016
On 15th September 2016, first patient for the SPIHF-203 trial in Clinical Hospital Center Zemun in Belgrade.

4 July 2017
SCIRENT has obtained necessary approvals from Medicines and Medical Devices Agency of Serbia (ALIMS) and ethical committees for the SPIHF-203 trial.

Also in news

SPIHF-203 Latest News

EtiCS Trial Latest News

KYMA Trial Latest News

KYMA Trial

First patient enrolled in ETiCS trial

MOLITOR introduced at the Heart Failure Congress 2013

© 2017 SciRent